-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
"Nuclear medicine" is closely related to people's lives
.
For example, in daily physical examinations to check whether a person is infected with Helicobacter pylori, doctors mostly use carbon 14 (C14) breath kits.
C14 is an isotope and belongs to the category of nuclear medicine
.
Nuclear medicine plays a huge role in the process of clinical diagnosis and treatment.
It is mainly divided into two parts: diagnosis and treatment, including nuclear medicine equipment and nuclear medicine
.
Among them, radionuclide therapy has the characteristics of strong targeting, good therapeutic effect, and high safety.
It has become an important treatment method for thyroid, tumor and other diseases, and has a broad clinical application prospect
.
However, at present, China's radionuclide therapy still faces some urgent problems that need to be resolved, including the delay in R&D, production, and supply of Chinese pharmaceutical companies, making it difficult to meet clinical needs; the long period of radiopharmaceutical approval; laws, regulations, and regulatory systems are not complete; inspections Or the cost of treatment is expensive, which hinders the healthy development of nuclear medicine in China to a certain extent
.
In recent years, with the implementation of the radiopharmaceutical MAH system and the rise of a number of innovative radiopharmaceutical companies, the nuclear medicine industry has ushered in rapid development
.
In addition, nuclear medicine was elevated to the national strategic level in the "14th Five-Year Plan", and "one county, one nuclear medicine department" was officially included in the plan
.
Not long ago, the eight ministries and commissions jointly issued the "Medical Isotope Mid- and Long-Term Development Plan (2021-2035)", which made arrangements for the development, production, radiopharmaceutical R&D, medical insurance policy, and industrial layout of medical isotopes
.
Generally speaking, under a series of favorable factors, the development of the industry will accelerate
.
Data show that in 2017, China's nuclear medicine departments (including separate PET/SPECT centers) totaled 853, while China's tertiary hospitals had 2,340, and there is huge room for growth.
It is expected that China's nuclear medicine departments will enter a rapid construction in the next 10 years.
Period
.
It is worth mentioning that due to the high challenges, the domestic nuclear medicine field is also an under-invested field.
.
However, there has been news recently that this field is ushering in capital! On December 21, Full-Life Technologies announced the completion of a seed round financing of 10 million US dollars.
The funds raised will be used to promote the development of research product pipelines and the construction of nuclear technology platforms.
The nuclear technology platform will solve nuclear Medical supply chain issues
.
This round of financing was jointly led by Become Capital and Ge Ding Venture Capital
.
In view of the characteristics of radioisotopes, nuclear medicine has unique supply chain production and logistics challenges
.
Full-Life is composed of a group of experienced entrepreneurs and scientists, and has a good track record in the construction of biomedical companies and the research and clinical development of radioisotopes, ranging from half-life to full life
.
Can help solve these challenges faced by nuclear medicine
.
According to data, Full-Life is a fully integrated international nuclear medicine company headquartered in Shanghai with operations in Europe
.
Its mission is: to unleash the power of half-life and bring hope of a complete life to patients around the world
.
The company seeks to have the full value chain of radioligand production, research, development and commercialization in order to bring more clinical benefits to patients
.
The company's core platform aims to solve two core problems in today's radiopharmaceuticals: 1) the ability to produce high-quality and quantitative radioisotopes to meet future needs, and 2) an innovative transformational and biological research platform for future radiopharmaceutical treatments
.
.
For example, in daily physical examinations to check whether a person is infected with Helicobacter pylori, doctors mostly use carbon 14 (C14) breath kits.
C14 is an isotope and belongs to the category of nuclear medicine
.
Nuclear medicine plays a huge role in the process of clinical diagnosis and treatment.
It is mainly divided into two parts: diagnosis and treatment, including nuclear medicine equipment and nuclear medicine
.
Among them, radionuclide therapy has the characteristics of strong targeting, good therapeutic effect, and high safety.
It has become an important treatment method for thyroid, tumor and other diseases, and has a broad clinical application prospect
.
However, at present, China's radionuclide therapy still faces some urgent problems that need to be resolved, including the delay in R&D, production, and supply of Chinese pharmaceutical companies, making it difficult to meet clinical needs; the long period of radiopharmaceutical approval; laws, regulations, and regulatory systems are not complete; inspections Or the cost of treatment is expensive, which hinders the healthy development of nuclear medicine in China to a certain extent
.
In recent years, with the implementation of the radiopharmaceutical MAH system and the rise of a number of innovative radiopharmaceutical companies, the nuclear medicine industry has ushered in rapid development
.
In addition, nuclear medicine was elevated to the national strategic level in the "14th Five-Year Plan", and "one county, one nuclear medicine department" was officially included in the plan
.
Not long ago, the eight ministries and commissions jointly issued the "Medical Isotope Mid- and Long-Term Development Plan (2021-2035)", which made arrangements for the development, production, radiopharmaceutical R&D, medical insurance policy, and industrial layout of medical isotopes
.
Generally speaking, under a series of favorable factors, the development of the industry will accelerate
.
Data show that in 2017, China's nuclear medicine departments (including separate PET/SPECT centers) totaled 853, while China's tertiary hospitals had 2,340, and there is huge room for growth.
It is expected that China's nuclear medicine departments will enter a rapid construction in the next 10 years.
Period
.
It is worth mentioning that due to the high challenges, the domestic nuclear medicine field is also an under-invested field.
.
However, there has been news recently that this field is ushering in capital! On December 21, Full-Life Technologies announced the completion of a seed round financing of 10 million US dollars.
The funds raised will be used to promote the development of research product pipelines and the construction of nuclear technology platforms.
The nuclear technology platform will solve nuclear Medical supply chain issues
.
This round of financing was jointly led by Become Capital and Ge Ding Venture Capital
.
In view of the characteristics of radioisotopes, nuclear medicine has unique supply chain production and logistics challenges
.
Full-Life is composed of a group of experienced entrepreneurs and scientists, and has a good track record in the construction of biomedical companies and the research and clinical development of radioisotopes, ranging from half-life to full life
.
Can help solve these challenges faced by nuclear medicine
.
According to data, Full-Life is a fully integrated international nuclear medicine company headquartered in Shanghai with operations in Europe
.
Its mission is: to unleash the power of half-life and bring hope of a complete life to patients around the world
.
The company seeks to have the full value chain of radioligand production, research, development and commercialization in order to bring more clinical benefits to patients
.
The company's core platform aims to solve two core problems in today's radiopharmaceuticals: 1) the ability to produce high-quality and quantitative radioisotopes to meet future needs, and 2) an innovative transformational and biological research platform for future radiopharmaceutical treatments
.
